annb0t
Top 20
MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA.
This new DEP® program will generate and evaluate additional DEP® Antibody Drug Conjugates (ADCs).
This new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC) agreement that Starpharma signed with MSD in February 2021 as well as an expanded DEP®...
>>> Read more: Starpharma signs new DEP® agreement with MSD
This new DEP® program will generate and evaluate additional DEP® Antibody Drug Conjugates (ADCs).
This new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC) agreement that Starpharma signed with MSD in February 2021 as well as an expanded DEP®...
>>> Read more: Starpharma signs new DEP® agreement with MSD
